🌍💧 This World ARDS Day. Aqualung Therapeutics' groundbreaking research and innovative therapies are paving the way for new treatments and hope for those affected by Acute Respiratory Distress Syndrome (ARDS). Together, we can support and spread awareness about this critical cause. #WorldARDSDay #AqualungTherapeutics #AquaThera
AQUALUNG THERAPEUTICS CORPORATION
生物技术
Tucson，Arizona 472 位关注者
Novel Immune-Based antibodies to improve health of the critically ill
关于我们
Aqualung Therapeutics (ALT) is developing multi-pronged strategies to address the development of severe lung inflammation which is essential to the severity and outcomes of acute and chronic lung disorders such as acute lung injury, ventilator-induced lung injury (VILI), idiopathic pulmonary fibrosis, and pulmonary hypertension. Effective FDA-approved drugs are either currently unavailable or extraordinarily modest in their ability to modify disease progression. No drug is currently available that is preventive or curative. Aqualung’s strategies, which include deployment of a human monoclonal antibody which targets a novel inflammatory mediator (nicotinamide phosphoribosyltransferase or NAMPT) will address the unmet need for novel, effective therapies for VILI, IPF, and pulmonary hypertension.
- 网站
-
http://aqualungtherapeutics.com
AQUALUNG THERAPEUTICS CORPORATION的外部链接
- 所属行业
- 生物技术
- 规模
- 2-10 人
- 总部
- Tucson，Arizona
- 类型
- 私人持股
- 创立
- 2010
- 领域
- Acute Respiratory Distress Syndrome (ARDS)、Radiation Induced Lung Injury、Prostate Cancer、ventilator induced lung injury、inflammatory disorders、NAMPT (nicotinamide phosphoribosyltransferase)、trauma-induced inflammatory lung injury、humanized mAb, eNamptorTM和Antibody-based therapies